Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company (HZNP) Stock Competitors & Peer Comparison
See (HZNP) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HZNP | $116.30 | +0.00% | 26.6B | 61.86 | $1.88 | N/A |
| LLY | $883.96 | -3.67% | 835.4B | 38.54 | $22.94 | +0.70% |
| JNJ | $227.50 | -1.37% | 548.1B | 20.60 | $11.04 | +2.28% |
| ABBV | $198.71 | -1.11% | 351.4B | 83.47 | $2.38 | +3.39% |
| AZN | $189.75 | -1.33% | 294.1B | 29.00 | $6.54 | +1.69% |
| NVS | $145.47 | -1.36% | 280.7B | 20.34 | $7.15 | +3.28% |
| MRK | $111.90 | -2.37% | 276.6B | 15.37 | $7.28 | +2.97% |
| AMGN | $344.55 | -1.17% | 185.7B | 24.18 | $14.25 | +2.79% |
| NVO | $41.16 | +6.87% | 182.9B | 11.40 | $3.61 | +4.53% |
| GILD | $130.40 | -2.42% | 161.7B | 15.99 | $8.15 | +2.45% |
Stock Comparison
HZNP vs LLY Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, LLY has a market cap of 835.4B. Regarding current trading prices, HZNP is priced at $116.30, while LLY trades at $883.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas LLY's P/E ratio is 38.54. In terms of profitability, HZNP's ROE is +0.11%, compared to LLY's ROE of +0.98%. Regarding short-term risk, HZNP is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check LLY's competition here
HZNP vs JNJ Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, JNJ has a market cap of 548.1B. Regarding current trading prices, HZNP is priced at $116.30, while JNJ trades at $227.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas JNJ's P/E ratio is 20.60. In terms of profitability, HZNP's ROE is +0.11%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, HZNP is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check JNJ's competition here
HZNP vs ABBV Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, ABBV has a market cap of 351.4B. Regarding current trading prices, HZNP is priced at $116.30, while ABBV trades at $198.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas ABBV's P/E ratio is 83.47. In terms of profitability, HZNP's ROE is +0.11%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, HZNP is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check ABBV's competition here
HZNP vs AZN Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AZN has a market cap of 294.1B. Regarding current trading prices, HZNP is priced at $116.30, while AZN trades at $189.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AZN's P/E ratio is 29.00. In terms of profitability, HZNP's ROE is +0.11%, compared to AZN's ROE of +0.23%. Regarding short-term risk, HZNP is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AZN's competition here
HZNP vs NVS Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVS has a market cap of 280.7B. Regarding current trading prices, HZNP is priced at $116.30, while NVS trades at $145.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVS's P/E ratio is 20.34. In terms of profitability, HZNP's ROE is +0.11%, compared to NVS's ROE of +0.33%. Regarding short-term risk, HZNP is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVS's competition here
HZNP vs MRK Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MRK has a market cap of 276.6B. Regarding current trading prices, HZNP is priced at $116.30, while MRK trades at $111.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MRK's P/E ratio is 15.37. In terms of profitability, HZNP's ROE is +0.11%, compared to MRK's ROE of +0.36%. Regarding short-term risk, HZNP is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MRK's competition here
HZNP vs AMGN Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AMGN has a market cap of 185.7B. Regarding current trading prices, HZNP is priced at $116.30, while AMGN trades at $344.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AMGN's P/E ratio is 24.18. In terms of profitability, HZNP's ROE is +0.11%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, HZNP is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AMGN's competition here
HZNP vs NVO Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVO has a market cap of 182.9B. Regarding current trading prices, HZNP is priced at $116.30, while NVO trades at $41.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVO's P/E ratio is 11.40. In terms of profitability, HZNP's ROE is +0.11%, compared to NVO's ROE of +0.61%. Regarding short-term risk, HZNP is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVO's competition here
HZNP vs GILD Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GILD has a market cap of 161.7B. Regarding current trading prices, HZNP is priced at $116.30, while GILD trades at $130.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GILD's P/E ratio is 15.99. In terms of profitability, HZNP's ROE is +0.11%, compared to GILD's ROE of +0.41%. Regarding short-term risk, HZNP is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GILD's competition here
HZNP vs PFE Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, PFE has a market cap of 153.5B. Regarding current trading prices, HZNP is priced at $116.30, while PFE trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas PFE's P/E ratio is 19.84. In terms of profitability, HZNP's ROE is +0.11%, compared to PFE's ROE of +0.09%. Regarding short-term risk, HZNP is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check PFE's competition here
HZNP vs BMY Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BMY has a market cap of 119.9B. Regarding current trading prices, HZNP is priced at $116.30, while BMY trades at $58.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BMY's P/E ratio is 16.97. In terms of profitability, HZNP's ROE is +0.11%, compared to BMY's ROE of +0.39%. Regarding short-term risk, HZNP is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BMY's competition here
HZNP vs SNY Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SNY has a market cap of 113B. Regarding current trading prices, HZNP is priced at $116.30, while SNY trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SNY's P/E ratio is 20.16. In terms of profitability, HZNP's ROE is +0.11%, compared to SNY's ROE of +0.11%. Regarding short-term risk, HZNP is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SNY's competition here
HZNP vs GSK Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GSK has a market cap of 109.6B. Regarding current trading prices, HZNP is priced at $116.30, while GSK trades at $54.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GSK's P/E ratio is 14.55. In terms of profitability, HZNP's ROE is +0.11%, compared to GSK's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GSK's competition here
HZNP vs BIIB Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BIIB has a market cap of 27.1B. Regarding current trading prices, HZNP is priced at $116.30, while BIIB trades at $184.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BIIB's P/E ratio is 20.95. In terms of profitability, HZNP's ROE is +0.11%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, HZNP is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BIIB's competition here
HZNP vs GRFS Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, HZNP is priced at $116.30, while GRFS trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GRFS's P/E ratio is 11.71. In terms of profitability, HZNP's ROE is +0.11%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, HZNP is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GRFS's competition here
HZNP vs OGN Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, OGN has a market cap of 2.9B. Regarding current trading prices, HZNP is priced at $116.30, while OGN trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas OGN's P/E ratio is 15.67. In terms of profitability, HZNP's ROE is +0.11%, compared to OGN's ROE of +0.26%. Regarding short-term risk, HZNP is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check OGN's competition here
HZNP vs CELG-RI Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CELG-RI has a market cap of 163.5M. Regarding current trading prices, HZNP is priced at $116.30, while CELG-RI trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, HZNP is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CELG-RI's competition here
HZNP vs CTOR Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CTOR has a market cap of 77.4M. Regarding current trading prices, HZNP is priced at $116.30, while CTOR trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CTOR's P/E ratio is -2.83. In terms of profitability, HZNP's ROE is +0.11%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, HZNP is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CTOR's competition here
HZNP vs SCLX Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, HZNP is priced at $116.30, while SCLX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLX's P/E ratio is -0.18. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, HZNP is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLX's competition here
HZNP vs MIRA Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MIRA has a market cap of 44.1M. Regarding current trading prices, HZNP is priced at $116.30, while MIRA trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MIRA's P/E ratio is -0.78. In terms of profitability, HZNP's ROE is +0.11%, compared to MIRA's ROE of -6.46%. Regarding short-term risk, HZNP is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MIRA's competition here
HZNP vs SRXH Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, HZNP is priced at $116.30, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SRXH's P/E ratio is -0.71. In terms of profitability, HZNP's ROE is +0.11%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, HZNP is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SRXH's competition here
HZNP vs SCLXW Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, HZNP is priced at $116.30, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLXW's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, HZNP is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLXW's competition here
HZNP vs BDSIW Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BDSIW's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, HZNP is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BDSIW's competition here
HZNP vs CRXT Comparison April 2026
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CRXT's P/E ratio is -0.02. In terms of profitability, HZNP's ROE is +0.11%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, HZNP is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CRXT's competition here